WebinarsNew
Deep DiveNew
Explore Business Standard

Indian pharma companies are expanding selectively in the US for complex products while retaining India as their manufacturing base despite Trump's tariff threat
Imported generics to remain tariff-free for two years; industry doubts US can build a cost-competitive manufacturing ecosystem within the transition period
Updated On: Jul 22 2026 | 11:37 PM ISTThe think tank says Indian generics may remain cost-competitive despite higher tariffs, but higher-value formulations and branded generics could face greater pressure
Updated On: Jul 22 2026 | 2:51 PM ISTDonald Trump has proposed phased tariffs of up to 200% on imported generic drugs by 2028 to boost US manufacturing. Here's why the move matters for India's pharma sector and bilateral trade
Updated On: Jul 22 2026 | 12:02 PM IST